Hypomelanotic Disorder Clinical Trials

Find Hypomelanotic Disorder Clinical Trials Near You

A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Status: Recruiting
Location: See all (35) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Eligible participants must have the following at both screening and baseline:

‣ A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months

⁃ Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet

⁃ BSA involvement of ≥0.5% on the face

⁃ F-VASI ≥0.5 and T-VASI ≥3, and

⁃ Either active or stable disease at both screening and baseline

Locations
United States
Arizona
Medical Dermatology Specialists
RECRUITING
Phoenix
Saguaro Dermatology - Phoenix
NOT_YET_RECRUITING
Phoenix
California
Center For Dermatology Clinical Research, Inc.
RECRUITING
Fremont
Northridge Clinical Trials
RECRUITING
Northridge
Cura Clinical Research - Oxnard
RECRUITING
Oxnard
Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
NOT_YET_RECRUITING
Santa Clarita
Florida
Health Clinical Research, LLC
RECRUITING
Miami
K2 Medical Research - Tampa
RECRUITING
Tampa
Georgia
Advanced Medical Research, PC.
RECRUITING
Sandy Springs
Indiana
Dawes Fretzin Clinical Research Group, LLC
RECRUITING
Indianapolis
Massachusetts
Brigham and Women's Hospital
NOT_YET_RECRUITING
Boston
Michigan
Revival Research Institute, LLC
RECRUITING
Troy
New Hampshire
Stracskin
RECRUITING
Portsmouth
New York
Equity Medical
RECRUITING
The Bronx
Texas
Accurate Clinical Research, Inc
RECRUITING
Humble
Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
RECRUITING
San Antonio
Utah
Jordan Valley Dermatology & Research Center
RECRUITING
South Jordan
Virginia
Clinical Research Partners, LLC
RECRUITING
Richmond
Other Locations
Belgium
Anima Diepenbeek
NOT_YET_RECRUITING
Diepenbeek
UZ Gent
NOT_YET_RECRUITING
Ghent
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
NOT_YET_RECRUITING
Liège
Canada
INTERMED Groupe Sante
RECRUITING
Chicoutimi
DermEffects
NOT_YET_RECRUITING
London
Dar Clinical Research - Ottawa - Hunt Club Road
NOT_YET_RECRUITING
Ottawa
The Centre for Dermatology
NOT_YET_RECRUITING
Richmond Hill
Research Toronto
NOT_YET_RECRUITING
Toronto
SIMa Recherche
NOT_YET_RECRUITING
Verdun
China
Peking University People's Hospital
NOT_YET_RECRUITING
Beijing
Hangzhou Third People's Hospital
NOT_YET_RECRUITING
Hangzhou
Shanghai Skin Disease Hospital
NOT_YET_RECRUITING
Shanghai
The University of Hong Kong-Shenzhen Hospital
NOT_YET_RECRUITING
Shenzhen
Poland
Centrum Badan Klinicznych PI-House sp. z o.o.
NOT_YET_RECRUITING
Gdansk
Diamond Clinic
NOT_YET_RECRUITING
Krakow
Dermedic Jacek Zdybski
NOT_YET_RECRUITING
Ostrowiec Świętokrzyski
Centrum Medyczne Ginemedica
NOT_YET_RECRUITING
Wroclaw
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
1-317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2026-04-14
Estimated Completion Date: 2027-09
Participants
Target number of participants: 60
Treatments
Experimental: LY4005130
LY4005130 administered intravenously (IV)
Placebo_comparator: Placebo
Placebo administered IV
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company

This content was sourced from clinicaltrials.gov